Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

CME VIDEO SERIES
Tardive Dyskinesia: Assessment and Treatment During a Pandemic
View a 4-part CME video series on assessing for and treating tardive dyskinesia during the COVID-19 pandemic.
Quiz: Which Treatment May Significantly Increase the Risk of TD?
A retrospective study involving 7985 veterans found which medication or medication class was associated with the highest risk of tardive dyskinesia?
Tardive Dyskinesia Assessment Still Mandated Despite COVID-19
Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych…
Reducing Antipsychotic Dosage May Increase Risk of Hospitalization
A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
Q&A: Updates From Dr. Rakesh Jain on Managing Tardive Dyskinesia
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, is educating clinicians on the latest research and strategies for treating tardive dyskinesia during the 2020 Psych Congress Regionals meetings. He shares some of his guidance here.
Establishing Optimal TD Treatment Strategies and Patient Access Plans
Sanjay Gupta, MD, shares strategies for the assessment and treatment of patients with tardive dyskinesia.
Telepsychiatry: Approaches and Adaptations for TD Assessment
Amberg Hoberg, PMHNP, BC, discusses the assessment of tardive dyskinesia in patients via telepsychiatry.
Short-Term and Potential Long-Term Impacts of Tardive Dyskinesia
Rajeev Kumar, MD, a leading authority in the identification and management of movement disorders, explains the short-term and potential long-term impacts of tardive dyskinesia.
Top 3 Challenges of Treating Patients With or at Risk of Developing TD
Gus Alva, MD, DFAPA, discusses three challenges clinicians may face in delivering health care to patients with, or at risk of developing, tardive dyskinesia during the COVID-19 pandemic.
Deutetrabenazine Offers Long-Term Benefit for Severe TD
Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
Adverse Events With Deutetrabenazine Titration Decrease During Maintenance
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
Back to Top